PepGen (NASDAQ:PEPG) Upgraded at Wall Street Zen

PepGen (NASDAQ:PEPG) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other brokerages also recently commented on PEPG. Weiss Ratings upgraded shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, September 22nd. HC Wainwright reiterated a “buy” rating on shares of PepGen in a report on Wednesday, September 9th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.40.

PepGen Trading Up 6.5%

Shares of PEPG stock opened at $2.47 on Friday. PepGen has a 12-month low of $1.31 and a 12-month high of $7.80. The company has a market cap of $171.07 million, a PE ratio of -1.89 and a beta of 2.02. The business’s fifty day simple moving average is $2.67 and its 200-day simple moving average is $3.00.

PepGen (NASDAQ:PEPG) last posted its earnings results on Thursday, August 6th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.02. On average, equities analysts forecast that PepGen will post -1.11 earnings per share for the current year.

Hedge Funds Weigh In On PepGen

Hedge funds and other institutional investors have recently modified their holdings of the company. Commodore Capital LP lifted its stake in PepGen by 31.6% in the 1st quarter. Commodore Capital LP now owns 4,475,000 shares of the company’s stock worth $7,921,000 after acquiring an additional 1,075,000 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in shares of PepGen in the 2nd quarter worth $4,664,000. BlackRock Inc. bought a new position in PepGen during the second quarter worth about $2,348,000. Kalehua Capital Management LLC bought a new position in shares of PepGen during the first quarter valued at about $1,770,000. Finally, GSA Capital Partners LLP bought a new position in shares of PepGen during the second quarter valued at $1,535,000. 58.01% of the stock is owned by institutional investors and hedge funds.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.